Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Four CRISPR Companies Reach Agreement in Patent Case

XTALKS VITALS NEWS

DNA

These four companies make up one side of the CRISPR patent interference case, which will decide who owns the licensing rights to the exciting new gene editing technique.

Share this!

December 20, 2016 | by Sarah Hand, M.Sc.

Four companies focusing on CRISPR gene editing have agreed to form an intellectual property (IP) alliance. CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences, and ERS Genomics have all agreed to honor their respective licensing deals with the co-owners of the IP, including the Regents of the University of California, Emmanuelle Charpentier, and the University of Vienna.

“We are pleased that we have come to this global agreement with Intellia, Caribou, ERS and the co-owners and other licensees of this foundational CRISPR/Cas9 technology IP,” said Dr. Rodger Novak, CEO of CRISPR Therapeutics. “We believe that the Charpentier-University of California-Vienna IP estate constitutes the foundational IP in the CRISPR/Cas9 editing space. Intellia, CRISPR Therapeutics, Caribou, and ERS view this agreement as enhancing the efforts to protect our shared intellectual property rights and support the ongoing development of our product candidates, as well as those of our corresponding partners and licensees.”



These four companies make up one side of the CRISPR patent interference case, which will decide who owns the licensing rights to the exciting new gene editing technique. The agreement ensures that all four companies respect each other’s global rights to the technology.

Jennifer Doudna and Emmanuelle Charpentier are credited with the co-discovery that the CRISPR-Cas9 system could be applied to gene editing in mammalian cells. Since then, the two have independently founded CRISPR-focused biotechs, with Doudna founding Caribou and Intellia, and Charpentier founding CRISPR and ERS.

“Through this agreement, we are ensuring alignment in our efforts to protect and prosecute the foundational CRISPR/Cas9 discoveries made by Dr. Doudna, Dr. Charpentier, and their teams, which have transformed the genomics field and unleashed new therapeutic possibilities,” said Nessan Bermingham, CEO and founder, Intellia Therapeutics. “This strengthens Intellia's IP position as we continue forging ahead with the discovery and development of therapies for patients worldwide.”


Keywords: CRISPR, Gene Editing, Intellectual Property


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Food Companies are Looking for the Next Sriracha

October 19, 2017 - The Sriracha trend might be coming to an end and companies are looking for the next big hot sauce star to feature in their line-up.

Featured In: Food News


CFIA Recalling Mechanically Tenderized Steaks in Canada for E. coli

October 19, 2017 - The Canadian Food Inspection Agency posted a recall for mechanically tenderized steaks at the request of Vantage Foods Inc. on Tuesday.

Featured In: Food News


Study: Gender May Be Important When Matching Blood Transfusion Recipients to Donors

October 19, 2017 - According to a new study published in JAMA, gender and a history of pregnancy among female donors may have an impact on how well blood donors and recipients can be matched.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Brexit – Separating Fact from Fiction


Evolving Best Practices for Working with Authors of Scientific Publications – Authorship and Beyond


Human Whole-Genome Sequencing in a New Era Defined by the Illumina® HiSeq X® and NovaSeq™ Platforms


Clinical Event Adjudication: Comprehensive and Efficient Dossier Review Using a Global On-Line Solution


Copyright © 2016-2017 Honeycomb Worldwide Inc.